Opioid analgesia may reduce efficacy of immune checkpoint inhibitors among advanced lung cancer patients
Opioid analgesia may reduce the efficacy of immune checkpoint inhibitors suggests a recent study published in the BMC Pulmonology medicine.
A retrospective clinical study was conducted to compare the prognosis between the opioid analgesic (OA) treated and OA-untreated groups and to evaluate the effect of opioid painkillers on the efficacy of immune checkpoint inhibitors (ICIs) in the treatment of advanced lung cancer patients. In addition, a subgroup analysis of the clinical characteristics of the enrolled patients was performed to explore possible influencing factors.
Yu X, Zhao L, Song B. Impact of opioid analgesics on the efficacy of immune checkpoint inhibitors in a lung cancer population. BMC Pulm Med. 2022 Nov 21;22(1):431. doi: 10.1186/s12890-022-02210-9. PMID: 36411438; PMCID: PMC9677634.
Yu X, Zhao L, Song B, impact, opioid, analgesics, efficacy, immune, checkpoint, inhibitors, lung cancer, population, BMC Pulm Med, Drug resistance, Gut microbiota, Immune checkpoint inhibitors, Lung cancer, Opioid analgesics.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd